Petter Bjornstad1, David Cherney, David M Maahs. 1. aDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA bDepartment of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Ontario, Canada cBarbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado, USA *David Cherney and David M. Maahs contributed equally to the writing of this article.
Abstract
PURPOSE OF REVIEW: Despite improvements in glycemic and blood pressure control in patients with type 1 diabetes, diabetic nephropathy remains the most common cause of chronic kidney disease worldwide. A major challenge in preventing diabetic nephropathy is the inability to identify high-risk patients at an early stage, emphasizing the importance of discovering new therapeutic targets and implementation of clinical trials to reduce diabetic nephropathy risk. RECENT FINDINGS: Limitations of managing patients with diabetic nephropathy with renin-angiotensin-aldosterone system blockade have been identified in recent clinical trials, including the failure of primary prevention studies in T1D and the demonstration of harm with dual renin-angiotensin-aldosterone system blockade. Fortunately, several new targets, including serum uric acid, insulin sensitivity, vasopressin, and sodium-glucose cotransporter-2 inhibition, are promising in the prevention and treatment of diabetic nephropathy. SUMMARY: Diabetic nephropathy is characterized by a long clinically silent period without signs or symptoms of disease. There is an urgent need for improved methods of detecting early mediators of renal injury, to ultimately prevent the initiation and progression of diabetic nephropathy. In this review, we will focus on early diabetic nephropathy and summarize potential new therapeutic targets.
PURPOSE OF REVIEW: Despite improvements in glycemic and blood pressure control in patients with type 1 diabetes, diabetic nephropathy remains the most common cause of chronic kidney disease worldwide. A major challenge in preventing diabetic nephropathy is the inability to identify high-risk patients at an early stage, emphasizing the importance of discovering new therapeutic targets and implementation of clinical trials to reduce diabetic nephropathy risk. RECENT FINDINGS: Limitations of managing patients with diabetic nephropathy with renin-angiotensin-aldosterone system blockade have been identified in recent clinical trials, including the failure of primary prevention studies in T1D and the demonstration of harm with dual renin-angiotensin-aldosterone system blockade. Fortunately, several new targets, including serum uric acid, insulin sensitivity, vasopressin, and sodium-glucose cotransporter-2 inhibition, are promising in the prevention and treatment of diabetic nephropathy. SUMMARY:Diabetic nephropathy is characterized by a long clinically silent period without signs or symptoms of disease. There is an urgent need for improved methods of detecting early mediators of renal injury, to ultimately prevent the initiation and progression of diabetic nephropathy. In this review, we will focus on early diabetic nephropathy and summarize potential new therapeutic targets.
Authors: Bruce A Perkins; Linda H Ficociello; Betsy E Ostrander; Kristen H Silva; Janice Weinberg; James H Warram; Andrzej S Krolewski Journal: J Am Soc Nephrol Date: 2007-02-28 Impact factor: 10.121
Authors: Lukas U Zimmerli; Eric Schiffer; Petra Zürbig; David M Good; Markus Kellmann; Laetitia Mouls; Andrew R Pitt; Joshua J Coon; Roland E Schmieder; Karlheinz H Peter; Harald Mischak; Walter Kolch; Christian Delles; Anna F Dominiczak Journal: Mol Cell Proteomics Date: 2007-10-19 Impact factor: 5.911
Authors: Constantin von Zur Muhlen; Eric Schiffer; Petra Zuerbig; Marcus Kellmann; Mario Brasse; Natalie Meert; Raymond C Vanholder; Anna F Dominiczak; Yung Chih Chen; Harald Mischak; Christoph Bode; Karlheinz Peter Journal: J Proteome Res Date: 2009-01 Impact factor: 4.466
Authors: Kasper Rossing; Harald Mischak; Mohammed Dakna; Petra Zürbig; Jan Novak; Bruce A Julian; David M Good; Joshua J Coon; Lise Tarnow; Peter Rossing Journal: J Am Soc Nephrol Date: 2008-04-30 Impact factor: 10.121
Authors: David M Maahs; Lorraine G Ogden; Adam Kretowski; Janet K Snell-Bergeon; Gregory L Kinney; Tomas Berl; Marian Rewers Journal: Diabetes Date: 2007-07-27 Impact factor: 9.461
Authors: Katherine R Tuttle; Janet B McGill; Douglas J Haney; Toni E Lin; Pamela W Anderson Journal: Clin J Am Soc Nephrol Date: 2007-05-30 Impact factor: 8.237
Authors: Marion M Mafham; Ioana Niculescu-Duvaz; Jeffrey Barron; Jonathan R Emberson; Mark E C Dockrell; Martin J Landray; Colin Baigent Journal: Nephron Clin Pract Date: 2007
Authors: David Z I Cherney; Ana Konvalinka; Bernard Zinman; Eleftherios P Diamandis; Anton Soosaipillai; Heather Reich; Joanne Lorraine; Vesta Lai; James W Scholey; Judith A Miller Journal: Diabetes Care Date: 2008-10-22 Impact factor: 19.112
Authors: Petter Bjornstad; David M Maahs; Marian Rewers; Richard J Johnson; Janet K Snell-Bergeon Journal: J Diabetes Complications Date: 2014-07-04 Impact factor: 2.852
Authors: David León Jiménez; David Z I Cherney; Petter Bjornstad; Luis Castilla-Guerra; José Pablo Miramontes González Journal: Am J Physiol Renal Physiol Date: 2018-08-01
Authors: Sripriya Raman; Hongying Dai; Stephen A DeLurgio; David D Williams; Marcus Lind; Susana R Patton; John A Spertus; Mikhail Kosiborod; Mark A Clements Journal: Pediatr Diabetes Date: 2015-09-17 Impact factor: 4.866
Authors: Petter Bjornstad; Laura Pyle; Gregory L Kinney; Marian Rewers; Richard J Johnson; David M Maahs; Janet K Snell-Bergeon Journal: J Diabetes Complications Date: 2016-06-14 Impact factor: 2.852